UBS Maintains Buy on BridgeBio Pharma, Lowers Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle maintains a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) but lowers the price target from $51 to $47.

May 28, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Eliana Merle maintains a Buy rating on BridgeBio Pharma but lowers the price target from $51 to $47.
The Buy rating suggests continued confidence in the stock's potential, but the lowered price target indicates a more cautious outlook on its near-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100